Poseida Therapeutics, Inc. (PSTX)
PSTX moved a median of +0.22% 30 minutes after news, and +0.49% by the close. How PSTX actually reacts to news — the realized, point-in-time move the market made, measured across 145 labeled events over the last three years with zero look-ahead.
PSTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.21% | 59% | 112 |
| 30-min | +0.22% | 58% | 113 |
| 60-min | +0.32% | 58% | 113 |
| to close | +0.49% | 59% | 113 |
| Middle 50% of PSTX reactions | -1.64% to +1.97% |
|---|---|
| Median reaction (30-min) | +0.22% |
| Measured reactions | 145 |
Half of all Poseida Therapeutics, Inc. news events land between -1.64% and +1.97% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PSTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | +0.22% | 80% | +0.54% |
| Rating reiterations | 26 | -0.02% | 50% | -0.33% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how PSTX ranks against every other measured name →
That’s how PSTX usually reacts — get an email when it moves on news →Email me when PSTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PSTX's baseline. Nothing else.
Recent PSTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Poseida Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Poseida Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Poseida Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Poseida Therapeutics, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Poseida Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.05% | +0.75% | |
| Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting | Press release | PR Newswire | +0.05% | +0.53% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Poseida Therapeutics, Inc. (Nasdaq – PSTX), Gatos Silver, Inc. (NYSE - GATO), Micropac Industries, Inc. (OTC - MPAD), Aerovate Therapeutics, Inc. (Nasdaq - AVTE) | Press release | GlobeNewswire | -0.05% | +0.91% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Poseida Therapeutics, Inc. (Nasdaq – PSTX), Air Transport Services Group, Inc. (Nasdaq– ATSG), Micropac Industries, Inc. (OTC - MPAD), Aerovate Therapeutics, Inc. (Na | Press release | GlobeNewswire | -0.04% | +0.23% | |
| Form 8-K Poseida Therapeutics, For: Nov 25 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | +1.19% | |
| Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. | Press release | PR Newswire | +0.22% | +1.19% | |
| PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.22% | +1.19% | |
| Form 8-K Poseida Therapeutics, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -0.60% | -3.60% | |
| Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline | Press release | PR Newswire | -0.60% | -3.60% | |
| Poseida Therapeutics to Present at Two Upcoming Investor Conferences | Press release | PR Newswire | -5.03% | +0.27% | |
| Form 10-Q Poseida Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +7.08% | -5.23% | |
| Form 8-K Poseida Therapeutics, For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +7.08% | -5.23% | |
| Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 | Press release | PR Newswire | +7.08% | -5.23% | |
| Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 | Press release | PR Newswire | +3.33% | +2.96% | |
| Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema | Press release | PR Newswire | +0.40% | -3.20% | |
| Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche | Press release | PR Newswire | +0.00% | -0.39% | |
| Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 | Press release | PR Newswire | +1.19% | +3.57% | |
| Form 8-K Poseida Therapeutics, For: Sep 27 | SEC filing · Form 8-K | SEC EDGAR | +2.45% | +10.00% | |
| Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients | Press release | PR Newswire | +2.45% | +10.00% | |
| Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma | Press release | PR Newswire | +0.00% | -5.96% | |
| Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting | Press release | PR Newswire | +1.58% | -4.91% | |
| Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma | Press release | PR Newswire | +1.58% | -4.91% | |
| Poseida Therapeutics to Present at Upcoming Investor Conferences | Press release | PR Newswire | +0.00% | +2.14% | |
| Form EFFECT Poseida Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -1.03% | +0.00% | |
| Form 10-Q Poseida Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.33% | +1.62% | |
| Form 8-K Poseida Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.33% | +1.62% | |
| Form S-3 Poseida Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.33% | +1.62% | |
| Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 | Press release | PR Newswire | +0.33% | +1.62% | |
| Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum | Press release | PR Newswire | +0.67% | +1.68% | |
| Form 8-K Poseida Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | +0.76% | |
| Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders | Press release | PR Newswire | +0.99% | -12.54% | |
| Form 10-Q Poseida Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +7.50% | +15.33% | |
| Form 8-K Poseida Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +7.50% | +15.33% | |
| Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 | Press release | PR Newswire | +7.50% | +15.33% | |
| Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting | Press release | PR Newswire | -2.56% | -1.09% | |
| Form EFFECT Poseida Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +1.04% | -2.08% | |
| Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology | Press release | PR Newswire | +1.11% | +2.97% | |
| Form 8-K Poseida Therapeutics, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +1.11% | +2.97% | |
| Form ARS Poseida Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.46% | +4.93% | |
| Form DEF 14A Poseida Therapeutics, For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | +2.46% | +4.93% | |
| Form DEFA14A Poseida Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +2.46% | +4.93% | |
| Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting | Press release | PR Newswire | +0.00% | -2.44% | |
| Form 8-K Poseida Therapeutics, For: Apr 17 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | +0.49% | |
| Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus | Press release | PR Newswire | -0.74% | +0.49% | |
| Form 8-K Poseida Therapeutics, For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | -0.84% | +0.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PSTX section they belong to.
Where else PSTX is measured.
PSTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Poseida Therapeutics, Inc.'s median reaction calculated?
Every labeled PSTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 145 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 58% of PSTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PSTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.